Levo-corydalmine attenuates microglia activation and neuropathic pain by suppressing ASK1-p38 MAPK/NF-κB signaling pathways in rat spinal cord.

Abstract

BACKGROUND AND OBJECTIVES:

Neuropathic pain is partially refractory to currently available treatments. Although some studies have reported that apoptosis signal-regulating kinase 1 (ASK1) may inhibit chronic pain, the mechanisms underlying this process have not been fully elucidated.

METHODS:

Chronic constriction injury (CCI) of the rat sciatic nerve was used to establish a neuropathic pain model. Nociception was assessed using von Frey hair and Hargreaves' methods. Western blot and immunofluorescence were used to detect the cell signaling pathway. BV2 cell line was cultured for in vitro evaluation.

RESULTS:

Our results indicated that spinal ASK1 was co-expressed with the microglia marker ionized calcium binding adaptor 1. Additionally, intrathecal administration of ASK1 inhibitor suppressed the activation of spinal microglia and attenuated CCI-induced neuropathic pain. The ASK1 inhibitor also decreased the levels of phosphorylated ASK1 (p-ASK1), p65, p38 mitogen-activated protein kinase (MAPK) and tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) messenger RNA in lipopolysaccharide-stimulated BV2 microglia cells. Intragastric administration of levo-corydalmine (l-CDL) significantly attenuated CCI-induced neuropathic pain and inhibited the expression of p-ASK1 in the spinal cord. l-CDL conspicuously suppressed the activation of spinal microglia in vitro and in vivo. Translocation of nuclearfactor-kappa B (NF-κB) and upregulation of p-p65, TNF-α, IL-1β were inhibited by l-CDL. Further, the analgesic effects of l-CDL were associated with reduced levels of phosphorylated protein kinase C (PKC γ), c-JunNH2-terminal kinase, and extracellular signal-regulated kinase.

CONCLUSIONS:

This study showed that the expression of ASK1 in spinal microglia and ASK1 inhibitor suppressed microglia activation via suppression of p38 MAPK/NF-κB, which ultimately attenuated CCI-induced neuropathic pain. l-CDL also inhibited the ASK1-P38 MAPK/NF-κB axis to attenuate CCI-induced neuropathic pain.

• Authors: Wen-Ling Dai, Yi-Ni Bao, Ji-Fa Fan, Shan-Shan Li, Wan-Li Zhao, Bo-Yang Yu, Ji-Hua Liu
• Journal: Regional anesthesia and pain medicine (Reg Anesth Pain Med) Vol. 45 Issue 3 Pg. 219-229 (03 2020) ISSN: 1532-8651 [Electronic] England
• PMID: 31898581 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © American Society of Regional Anesthesia & Pain Medicine 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Chemical References

• IL1B protein, rat
• Interleukin-1beta
• NF-kappa B
• Tumor Necrosis Factor-alpha
• Berberine
• corydalmine
• p38 Mitogen-Activated Protein Kinases
• MAP Kinase Kinase Kinase 5

Topics

• Animals
• Berberine (analogs & derivatives, pharmacology)
• Interleukin-1beta (metabolism)
• MAP Kinase Kinase Kinase 5 (metabolism)
• Male
• Microglia (metabolism)
• NF-kappa B (metabolism)
• Neuralgia (drug therapy, metabolism)
• Rats
• Rats, Sprague-Dawley
• Sciatic Nerve
• Signal Transduction (drug effects)
• Spinal Cord (metabolism)
• Tumor Necrosis Factor-alpha (metabolism)
• p38 Mitogen-Activated Protein Kinases (metabolism)